article thumbnail

Healthcare HR: Addressing Key Risks in 2024

XTalks

Mercer and Marsh recently released its “ 2024 People Risk Report ,” which highlights critical areas for healthcare HR professionals. Let’s delve into why these points are crucial for healthcare HR professionals, ensuring resilient and effective management of workforces. The collaboration between HR and risk professionals is vital.

HR 52
article thumbnail

eBook: HR Development within the Life Sciences Industry

XTalks

Disruption is very commonly witnessed in the life sciences industry hence human resources (HR) departments need to continuously come up with new talent strategies and recruitment practices to stay progressive. . Are you looking to understand the powerful impact HR has on the overall success of the global life science industry?

HR 104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In an Evolving Market, HR Leaders Balance Business Needs with Employee Engagement

BioSpace

BioSpace spoke to HR leaders about how they have been supporting companies navigating a challenging economy while meeting the needs of the workforces they support.

HR 63
article thumbnail

SABCS: Pharmas show their working in HR+/HER2- breast cancer

pharmaphorum

There was also new data from the monarchE trial of Eli Lilly’s CDK 4/6 inhibitor Verzenio (abemaciclib) in combination with endocrine therapy as an adjuvant treatment for patients with high risk, early-stage HR+/HER2- breast cancer. The post SABCS: Pharmas show their working in HR+/HER2- breast cancer appeared first on.

HR 96
article thumbnail

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Pharma Mirror

The post Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval appeared first on Pharma Mirror Magazine. Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an ?-specific

HR 130
article thumbnail

Increasing the Business Value of Your HR Data: Integrate to Innovate

XTalks

HR organizations rely on access to employee data to address regulatory requirements, support modernization projects, manage talent, and address mergers and acquisitions. Why is having the right HR technology so important? Drive Innovation.

HR 87
article thumbnail

Truqap Combination Approved by FDA for HR-Positive, HER2-Negative Locally Advanced, Metastatic Breast Cancer

Pharmaceutical Commerce

The FDA also approved a companion diagnostic test to detect the PIK3CA, AKT1, and PTEN alterations as part of the approval for AstraZeneca’s capivasertib (Truqap) plus fulvestrant (Faslodex) for HR-positive, HER2-negative locally advanced or metastatic breast cancer.

HR 52